Joe Woody

Since 2009, Joe Woody has headed the Vascular Therapies division of Covidien, an international healthcare company with U.S. headquarters in Mansfield, Massachusetts. As President of Vascular Therapies, Joe Woody draws upon approximately two decades of sales and marketing experience to spearhead Covidien’s continued growth within the medical technology industry.

In the span of two years, Joe Woody has contributed significantly to the expansion of the Covidien product portfolio, proving instrumental in the 2010 acquisition of ev3 Inc. During Mr. Woody’s tenure, Covidien also gained pre-market approval for its Pipeline® Embolization Device and 510(k) clearances for its Kendall SCD™ Compression Comfort Sleeve, Kendall SCD™ 700 Series Controller, and TurboHawk™ Plaque Excision System from the U.S. Food and Drug Administration.

Outside of his duties at Covidien, Joe Woody also contributes to the development of Systagenix, which appointed him in July 2011 to its Board of Directors. Based in the United Kingdom with locations on five continents, Systagenix provides advanced wound care products and diagnostic tests to healthcare professionals throughout the world.

Over the years, Joe Woody has worked for a number of other medical device companies, including Acuson, Alliance Imaging, GE Medical Systems, and, most recently, Smith & Nephew. While at Smith & Nephew, Mr. Woody served as Vice President and General Manager for the Clinical Therapies Division, and then as President of Advanced Wound Management.